Reproductive Medicine
High-yield reproductive medicine for USMLE Step 1/2/3 — breast cancer screening and pharmacology, infertility mechanisms, disorders of sexual differentiation, and the HPG axis. Organized by cluster for exam performance.
By Dr. Marish Asudani · Published · Updated
Which Divine Intervention episodes cover reproductive medicine for the USMLE?
This guide covers 4 Divine Intervention episodes plus 1 Rapid Review inline for Step 1/2/3 reproductive medicine: disorders of sexual differentiation and CAH (EP357), breast cancer (EP309), infertility and the prolactin/HPG axis (EP493), and androgen insensitivity vs Müllerian agenesis (RR 100). Treat breast cancer questions as decision-tree problems: risk stratification, screening modality selection and chemoprevention choice (tamoxifen vs raloxifene vs aromatase inhibitors). For sexual differentiation, know what testosterone does, what DHT does and which ducts depend on which hormone.
- Testosterone → Wolffian duct: Testosterone (from Leydig cells) drives development of epididymis, vas deferens, seminal vesicles. DHT (5α-reductase converts T→DHT) drives external virilization: prostate, external genitalia, male external appearance
- AMH (Müllerian-inhibiting factor): Produced by Sertoli cells; nukes the Müllerian duct → prevents development of fallopian tubes, uterus, cervix, upper vagina in XY individuals
- 5α-reductase deficiency: XY male; internally male (Wolffian intact), externally ambiguous at birth → virilizes at puberty (testosterone surges, partial external development occurs). Testes in inguinal canal or labia
- Congenital adrenal hyperplasia (21-OH deficiency): XX female most common — virilized external genitalia (clitoromegaly, labial fusion) but internal female structures intact. Salt-wasting crisis = hyponatremia + hyperkalemia + hypotension in neonates
- Turner syndrome (45XO): Streak ovaries → hypergonadotropic hypogonadism (high FSH/LH, no negative feedback); coarctation of aorta, horseshoe kidney, bicuspid aortic valve, primary amenorrhea, short stature
- Klinefelter syndrome (47XXY): Male phenotype; small firm testes; ↓ testosterone → ↑ FSH/LH; gynecomastia; infertility; increased breast cancer risk; long extremities
Androgen Physiology — The Core Framework
| Hormone | Source | Action | Target Structure |
|---|---|---|---|
| Testosterone | Leydig cells (LH-stimulated) | Wolffian duct development | Epididymis, vas deferens, seminal vesicles |
| DHT | T → DHT via 5α-reductase in target tissues | External virilization | Prostate, external genitalia, male external appearance |
| AMH (MIF) | Sertoli cells (FSH-stimulated) | Destroys Müllerian duct | Prevents fallopian tubes, uterus, cervix, upper vagina |
| Estrogen | Granulosa cells (FSH-stimulated) | Breast development, uterine growth | Breast tissue, endometrium (Tanner stage) |
| Androgens | Theca cells (LH-stimulated) | Pubic + axillary hair | Hair follicles (both male and female) |
21-hydroxylase deficiency (most common CAH): Blocks cortisol AND aldosterone. Results: ↑ androgens → virilization. Salt-wasting (hyponatremia, hyperkalemia) in severe form. XX female = most tested presentation (virilized female).
11β-hydroxylase deficiency: Blocks cortisol only. Aldosterone precursors (11-deoxycorticosterone) accumulate → hypertension. ↑ androgens → virilization. Key differentiator: HTN + virilization = 11β-OH deficiency.
Gonadotropin Patterns in Key Disorders
| Condition | FSH / LH | Estrogen | Reason |
|---|---|---|---|
| Turner syndrome (45XO) | ↑↑ (hypergonadotropic) | ↓↓ | Streak ovaries → no feedback |
| Klinefelter (47XXY) | ↑↑ (hypergonadotropic) | Normal–↑ (gynecomastia) | Seminiferous tubule failure → no feedback |
| Kallmann syndrome | ↓↓ (hypogonadotropic) | ↓↓ | GnRH neuron migration failure + anosmia |
| PCOS | Normal (LH:FSH ratio >2) | Normal | Anovulation without gonadotropin failure |
| Premature ovarian failure | ↑↑ | ↓↓ | Ovarian failure <40 y/o → no feedback |
- Biggest risk factor: Age (but if biopsy-proven atypical ductal hyperplasia is listed alongside age, pick atypical ductal hyperplasia — premalignant disease trumps age as a risk factor)
- BRCA mutations: Annual mammogram + breast MRI starting age 25–30; prophylactic bilateral mastectomy + THBSO (total abdominal hysterectomy + bilateral salpingo-oophorectomy). Linked to BRCA1/2 = DNA repair defects
- Screening rules (USMLE): Age 40+ → mammogram every 1–2 years. Under 30 → ultrasound (denser breast tissue → mammogram less sensitive). Recent negative mammogram (<few months) + new mass → ultrasound next, not repeat mammogram
- Chemoprevention: GAIL risk ≥1.7% → chemoprevention. Premenopausal → tamoxifen (ER antagonist in breast, agonist in bone/uterus → endometrial cancer risk + VTE risk). Postmenopausal → aromatase inhibitor (anastrozole, letrozole, exemestane) — no VTE or endometrial risk
- HER2+ breast cancer: Bad prognosis but targetable. Trastuzumab (anti-HER2 monoclonal Ab) → ADCC killing mechanism; reversible dilated cardiomyopathy. Doxorubicin → irreversible cardiomyopathy (prevent with dexrazoxane). Pre-chemo echo to check EF
- Prognosis: Most important prognostic factor = axillary lymph node involvement (or metastasis). Sentinel lymph node biopsy first → if positive, proceed to axillary dissection (risk of chronic lymphedema → lymphangiosarcoma)
Breast Mass Evaluation Algorithm
| Age | First Step | If Solid Mass | If Cystic Mass |
|---|---|---|---|
| <30 years | Ultrasound | Mammogram + core needle biopsy | Fine needle aspiration; bloody → cytology |
| >30 years | Mammogram | Core needle biopsy for tissue diagnosis | FNA; bloody aspirate → cytology |
| Any age, recent negative mammogram | Ultrasound (even if >30) | Proceed to biopsy despite negative imaging | — |
| Palpable mass, negative mammogram | Biopsy anyway | Never rely on negative imaging if palpable mass | — |
Tamoxifen: ER antagonist in breast (good) but ER agonist in uterus (bad → endometrial cancer) and bone (good → reduces osteoporosis). Also causes VTE. Use premenopausal. Limit to 5 years. Stop at menopause.
Aromatase inhibitors (anastrozole, letrozole, exemestane): Block adipose cell aromatase → no estrogen production. No VTE risk. No endometrial cancer risk. Use postmenopausal. Cause hot flashes (estrogen deficiency).
Breast Cancer Subtypes — HY Details
| Type | Presentation | Treatment Pearl |
|---|---|---|
| ER/PR positive | Most common; hormone-driven | Tamoxifen (pre-M) or AI (post-M) |
| HER2 positive | Bad prognosis; targetable | Trastuzumab (reversible cardiomyopathy) |
| Inflammatory breast cancer | Peau d'orange (skin dimpling); high fevers; weeks-long course → not mastitis | Do not mistake for infection |
| DCIS | Ductal carcinoma in situ | Lumpectomy + radiation = mastectomy (same survival, more local recurrence with lumpectomy) |
| Triple negative | No ER, PR, HER2 | Only chemotherapy; worst prognosis |
Unilateral bloody nipple discharge = intraductal papilloma (most common). Postmenopausal greenish discharge + lymphoplasmacytic infiltrate on biopsy = mammary duct ectasia. Galactorrhea = prolactinoma, antipsychotics, metoclopramide, hypothyroidism.
- Definition: Infertility = unable to conceive after 12 months unprotected sex. Begin workup at 6 months if age >35. Biggest risk factor = age (if no specific cause listed)
- PCOS: Anovulation → irregular menses → infertility. Hormone levels generally normal (normal gonadotropic amenorrhea). BMI ↑, insulin resistance (acanthosis nigricans), LH:FSH ratio >2. First-line for fertility = clomiphene (SERM)
- Endometriosis: 3 Ds — dysmenorrhea, dyspareunia, dyschezia (painful defecation). Most infertility questions about endometriosis frame it as an infertility question with these 3 symptoms as context clues
- Varicocele: "Bag of worms" on scrotal exam; pampiniform plexus dysfunction → elevated testicular temperature → impaired spermatogenesis (sperm needs 2°C below core temp). Left-sided more common (left gonadal vein → left renal vein at 90° angle)
- Anti-sperm antibodies: After testicular trauma or infection → breakdown of blood-testis barrier → sperm antigens exposed to immune system → antibodies destroy sperm. Normal hormone levels, normal exam = diagnosis of exclusion
- Primary ciliary dyskinesia (Kartagener): Dynein arm mutation → impaired cilia everywhere. Triad: recurrent sinopulmonary infections + bronchiectasis + situs inversus (apex on right). Infertility via impaired fallopian tube cilia + impaired sperm motility. Hearing loss (middle ear cilia)
Infertility Vignette Master Table
| Clinical Clue | Diagnosis | Mechanism | Gonadotropin Pattern |
|---|---|---|---|
| Short stature, low-extremity claudication, primary amenorrhea | Turner syndrome (45XO) | Streak ovaries | Hypergonadotropic hypogonadism |
| BMI 34, acanthosis nigricans, irregular menses every 3–4 months | PCOS | Anovulation | Normal gonadotropic amenorrhea |
| Breastfeeding mother, infertile | Lactation-induced | Prolactin → GnRH suppression | Hypogonadotropic hypogonadism |
| Poor sense of smell + infertility | Kallmann syndrome | GnRH neuron migration failure | Hypogonadotropic hypogonadism |
| Anorexia (low BMI, calluses on fingers) | Anorexia nervosa | HPG axis shutdown (starvation) | Hypogonadotropic hypogonadism |
| Multiple DNCs, infertile, normal hormones | Asherman syndrome | Endometrial stem cell destruction | Normal gonadotropic amenorrhea |
| Testicular trauma, normal exam + hormones | Anti-sperm antibodies | Blood-testis barrier breakdown | Normal |
| CF patient (elevated sweat chloride) | Cystic fibrosis | Male: agenesis of vas deferens; Female: thick cervical mucus | Normal |
| Recurrent sinopulmonary + situs inversus | Kartagener (primary ciliary dyskinesia) | Dynein arm defect → no ciliary beating | Normal |
| Antipsychotic use (risperidone) + infertility | Drug-induced hyperprolactinemia | D2 blockade → tuberoinfundibular pathway → ↑ prolactin | Hypogonadotropic hypogonadism |
- Antipsychotics (especially risperidone) — D2 blockade at tuberoinfundibular pathway
- Metoclopramide (diabetic gastroparesis) — also a D2 blocker
- Verapamil (non-dihydropyridine CCB for angina/arrhythmia) — directly elevates prolactin
- Opioids — chronic use → prolactin elevation
- TRH elevation (hypothyroidism) — TRH is powerful prolactin stimulator → hypothyroidism can cause infertility via prolactin
- MEN1 + infertility: Pituitary prolactinoma in MEN1 (Para-Pan-Pit mnemonic: Parathyroid + Pancreatic neuroendocrine + Pituitary) → hyperprolactinemia → GnRH suppression → infertility. Autosomal dominant
- CKD + infertility: Kidneys clear prolactin → CKD → hyperprolactinemia → HPG axis shutdown → infertility
- Premature ovarian failure: Ovarian failure <40 years old → hypergonadotropic hypogonadism (↑ FSH/LH) + menopausal symptoms (hot flashes). Diagnosed in women under 40 with these findings
- Fallopian tube scarring (PID/TB): Pelvic inflammatory disease or TB → scarring of fallopian tubes → impaired egg transport (cilia can't beat) → infertility. Most common infective cause post-PID
- Male semen quality: Biggest male risk factor (after age) = semen quality (motility, count, morphology). Cryptorchidism → elevated testicular temperature → impaired spermatogenesis
- Hypogonadotropic vs hypergonadotropic: Hypogonadotropic = problem above gonads (hypothalamus/pituitary). Hypergonadotropic = problem at gonad level (streak ovaries, testes fail). Normal gonadotropic = anatomical/anovulatory (PCOS, Asherman)
The Prolactin Cascade — Why It Causes Infertility
Prolactin → inhibits GnRH (at hypothalamus) → decreased FSH and LH → gonads not stimulated → hypogonadotropic hypogonadism. This is why anything that raises prolactin causes amenorrhea and infertility. It is a physiologic mechanism (lactation) repurposed as pathology when triggered by drugs or tumors.
Hypothyroidism → low T3/T4 → no negative feedback → TRH rises → TRH is a potent prolactin stimulator → prolactin rises → GnRH suppressed → infertility. Also: lower T3 → fewer cardiac beta-1 receptors → low heart rate. This chain explains the bradycardia + amenorrhea + weight gain triad of hypothyroidism.
Tuberoinfundibular Dopamine Pathway
Dopamine from the hypothalamus inhibits prolactin secretion via the tuberoinfundibular pathway. Block dopamine (D2 receptor) → prolactin rises. This is why antipsychotics (D2 blockers), metoclopramide, and bromocriptine (dopamine agonist used to treat prolactinomas) all have predictable effects on prolactin.
Treatment of Prolactinomas
| Tumor Size | First-Line Treatment | Drug Mechanism |
|---|---|---|
| Microprolactinoma (<1 cm) | Dopamine agonist (cabergoline > bromocriptine) | D2 agonism → prolactin suppression + tumor shrinkage |
| Macroprolactinoma (>1 cm) with vision loss | Dopamine agonist first; surgery if refractory | Same mechanism; surgery for optic chiasm compression |
- Androgen insensitivity syndrome (AIS / testicular feminization): 46XY genotype. Testosterone receptor non-functional → no virilization despite male genotype. Phenotypically female. Testes produce AMH (nukes Müllerian duct → no uterus, fallopian tubes, upper vagina) but testosterone doesn't act → no Wolffian structures either
- AIS Tanner staging: Breasts = Tanner 4–5 (estrogen works fine from testes). Pubic/axillary hair = Tanner 1–2 (androgen receptor broken → no pubic/axillary hair). This combination is pathognomonic
- Müllerian agenesis (MRKH syndrome): 46XX genotype. Ovaries intact (ovaries are not Müllerian-derived). Phenotypically female. Müllerian duct fails to develop → no uterus, fallopian tubes, upper vagina. But ovaries produce estrogen AND androgens normally
- MRKH Tanner staging: Breasts = Tanner 4–5 (estrogen normal). Pubic/axillary hair = Tanner 4–5 (androgens from ovary normal). Both sexualization markers fully developed — distinguishes from AIS
- Why both have primary amenorrhea: AIS = testes make AMH → no uterus → no menses. MRKH = Müllerian duct fails → no uterus → no menses. Both lack a uterus but for completely different reasons
- Gonad type: AIS = testes (in inguinal canal or labia — increased malignancy risk → prophylactic orchiectomy after puberty). MRKH = ovaries (normal, no increased cancer risk)
AIS vs Müllerian Agenesis — The Two-Feature Framework
| Feature | AIS (Testicular Feminization) | Müllerian Agenesis (MRKH) |
|---|---|---|
| Genotype | 46XY | 46XX |
| Phenotype | Female | Female |
| Gonad type | Testes (in inguinal canal or labia) | Ovaries (normal position) |
| Uterus / fallopian tubes | Absent (AMH from testes destroys Müllerian duct) | Absent (duct fails to develop) |
| Breast development | Normal / advanced (Tanner 4–5) | Normal / advanced (Tanner 4–5) |
| Pubic / axillary hair | Tanner 1–2 (androgen receptor defect) | Tanner 4–5 (androgen receptor intact) |
| Testosterone level | Normal or elevated (can't respond to it) | Normal female range |
| Cancer risk of gonad | Elevated (testicular gonadoblastoma) — remove after puberty | None |
Both AIS and MRKH present with: (1) primary amenorrhea, (2) female external appearance, (3) absent uterus, (4) good breast development. The ONLY reliable differentiator is pubic/axillary hair Tanner staging and genotype. If the question says "no pubic hair" or "sparse pubic hair" — AIS. If pubic hair is normal — MRKH.
Why AIS Has No Wolffian Structures Either
In normal male development, testosterone drives Wolffian duct development. In AIS, testosterone receptor is broken → testosterone cannot act → Wolffian duct also regresses. The person is 46XY but has neither Müllerian derivatives (destroyed by AMH) nor Wolffian derivatives (can't respond to testosterone). Result: phenotypic female with a blind-ending vaginal pouch and no internal reproductive organs.
- 21-hydroxylase deficiency (most common CAH): Blocks cortisol + aldosterone. Shunts steroid precursors to androgens. XX female → virilized external genitalia (clitoromegaly, labial fusion, ambiguous genitalia) but internal structures (uterus, ovaries) intact because ovaries not affected
- Salt-wasting crisis (severe 21-OH deficiency): No aldosterone → hyponatremia + hyperkalemia + hypotension. Presents in first weeks of life as dehydration + shock. Treat with hydrocortisone + fludrocortisone (mineralocorticoid replacement)
- 11β-hydroxylase deficiency: Blocks cortisol only. 11-deoxycorticosterone accumulates (potent mineralocorticoid) → hypertension (not salt-wasting). Still virilized. Key differentiator: CAH + hypertension = 11β-OH deficiency
- True precocious puberty: GnRH-dependent (central): early activation of HPG axis. Breast/pubic hair + accelerated growth + advanced bone age. Treat with GnRH agonist (paradoxically suppresses pulsatile GnRH → suppresses FSH/LH)
- Pseudoprecocious puberty: GnRH-independent (peripheral): steroids produced outside HPG axis control (CAH, McCune-Albright, exogenous steroids). Treat underlying cause. GnRH agonist will NOT work here
- 17α-hydroxylase deficiency: No sex steroids (no androgen, no estrogen) + no cortisol but aldosterone excess → hypertension + hypokalemia. XY individual: phenotypically female (no DHT, no testosterone action). XX individual: primary amenorrhea with no secondary sex characteristics
CAH Enzyme Deficiency Comparison
| Enzyme Deficient | Cortisol | Aldosterone | Sex Steroids | Electrolyte Effect | Classic Presentation |
|---|---|---|---|---|---|
| 21-hydroxylase (most common) | ↓ | ↓ | ↑ androgens | Hyponatremia, hyperkalemia (salt-wasting) | Virilized XX female; salt-wasting crisis neonate |
| 11β-hydroxylase | ↓ | ↓ (but 11-DOC ↑) | ↑ androgens | Hypertension, hypokalemia (11-DOC mineralocorticoid) | Virilized female + hypertension |
| 17α-hydroxylase | ↓ | ↑ (aldosterone excess) | ↓↓ (no sex steroids) | Hypertension, hypokalemia | No sexual development; XY phenotypically female; XX no puberty |
Cholesterol → Pregnenolone → Progesterone → 17-OH-Progesterone → Androstenedione → Testosterone → DHT (and estrogen via aromatase). 21-OH converts progesterone → 11-deoxycorticosterone (toward aldosterone path) AND 17-OH-progesterone → 11-deoxycortisol (toward cortisol path). Block it → cortisol and aldosterone both fail, all precursors pile up and divert to androgens.